GGrantIndex
Sort

261,768 grants matching gene therapy

University of Washington Obstetric-fetal Pharmacology Research Unit

$1,002,006
Mary F Hebert · University Of Washington · U10 · FY2010 · HD

Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS Therapy in Alcohol Addiction Treatment

$1,001,961
Roger Brooks Bagwell · Actuated Medical, Inc. · R44 · FY2024 · AA

A Novel Immunological-Directed Live Biotherapy Product for Treating Ulcerative Colitis

$1,001,952
Gary Fanger · Rise Therapeutics, Llc · R44 · FY2023 · DK

Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

$1,001,898
Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2019 · CA

HIV-1 Maturation

$1,001,849
Eric Freed · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Center for Gene Therapy of Cystic Fibrosis and Other Ge*

$1,001,840
John F Engelhardt · University Of Iowa · P30 · FY2007 · DK

Sequencing Technology Core

$1,001,799
Donna Muzny · Baylor College Of Medicine · U19 · FY2019 · AI

Preclinical Development of an NT3-expressing HSV Vector

$1,001,774
David J. Fink · University Of Michigan At Ann Arbor · U01 · FY2011 · NS

Metal Chelate Conjugated Monoclonal Antibodies for Tumor Diagnosis and Therapy

$1,001,634
Martin W Brechbiel · Division Of Clinical Sciences - Nci · ZIA · FY2015 · CA

Informative Clinical Studies in Asthma

$1,001,474
Brigham And Women'S Hospital · U10 · FY2005 · HL

Development of a first-in-class therapeutic for producing 'on-demand' voiding

$1,001,467
Karl B Thor · Dignify Therapeutics, Llc · R44 · FY2018 · DK

Dynamics and Genetics of HIV Proviruses before and during Antiretroviral Therapy

$1,001,426
Mary Kearney · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Novel and functionally selective 5-HT2C receptor agonist for treating Alcohol Use Disorder

$1,001,425
Jeremy Forest · Kuleon Llc · U43 · FY2025 · AA

Microfluidic cell squeezing platform for the transdifferentiation of somatic cells for efficient generation of a cell replacement therapy for Parkinsons Disease

$1,001,356
Devin Bridgen · Sqz Biotechnologies Company, Inc. · R44 · FY2022 · GM

Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CF

$1,001,346
Christopher Hooper Goss · University Of Washington · UM1 · FY2013 · HL

Cell-free assay technologies for the identification of active compounds

$1,001,166
Barry Okeefe · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Clinical production of viral vectors for cancer gene therapy

$1,001,150
Steven Feldman · Division Of Basic Sciences - Nci · ZIC · FY2015 · CA

Identification of radiosensitizers for prostate cancer

$1,001,043
Travis Stracker · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes

$1,001,040
John M Maris · Children'S Hosp Of Philadelphia · R35 · FY2019 · CA

Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer

$1,001,029
Yicheng Wang · Immunova Therapeutics, Llc · R44 · FY2024 · CA

Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS

$1,001,024
Thomas Edward Smithgall · Fox Chase Chemical Diversity Center, Inc · R42 · FY2016 · GM

Age-Related Macular Degeneration: Genetic Variations and Animal Model

$1,000,820
Chi-Chao Chan · National Eye Institute · ZIA · FY2012 · EY

DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer

$1,000,745
Mike Glode · Aurora Oncology, Inc. · R44 · FY2020 · CA

Endothelial Dysfunction, Biomarkers and Lung Function

$1,000,726
Columbia University Health Sciences · R01 · FY2004 · HL

Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy

$1,000,669
Irving Lerner Weissman · Stanford University · R35 · FY2023 · CA